TD Cowen analyst Ritu Baral last night downgraded Morphic (MORF) to Hold from Buy without a price target after the company agreed to be acquired by Eli Lilly (LLY) for a purchase price of $57 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF:
- M&A News: Eli Lilly Snaps Up Morphic in $3.2B Deal
- Eli Lilly to acquire Morphic for $57 per share
- Eli Lilly to acquire Morphic for $57 per share in cash
- Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
- Morphic to Participate in Jefferies Global Healthcare Conference